Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panitumumab Pivotal Study Shows Increase In Progression-Free Survival

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen/Abgenix say twelve-month survival data will be released by second quarter. Rolling BLA submission will begin by year-end, wrapping up in early 2006.

You may also be interested in...



Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer

Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.

Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer

Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.

Amgen To Acquire Panitumumab Development Partner Abgenix

The companies plan to submit a BLA for colorectal cancer agent panitumumab later this week.

Related Content

Topics

UsernamePublicRestriction

Register

PS061330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel